May 9 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES REAFFIRMS FISCAL 2019 GUIDANCE AND ANNOUNCES UPCOMING CONFERENCE PARTICIPATION.FY2019 REVENUE VIEW $52.0 MILLION -- REFINITIV IBES DATA.
Full Article
May 8 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES NAMES RICHARD B. HANCOCK AS INTERIM PRESIDENT AND CHIEF EXECUTIVE OFFICER.AVID BIOSERVICES INC - HANCOCK WILL ALSO CONTINUE TO SERVE ON AVID'S BOARD OF DIRECTORS.AVID BIOSERVICES INC - HANCOCK SUCCEEDS ROGER J. LIAS, PH.D., WHO HAS RESIGNED FROM COMPANY AND ITS BOARD OF DIRECTORS.AVID BIOSERVICES INC - IS COMMENCING A SEARCH FOR A PERMANENT CHIEF EXECUTIVE OFFICER..
Full Article
Dec 10 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR SECOND QUARTER FISCAL 2019 AND RECENT DEVELOPMENTS.Q2 LOSS PER SHARE $0.05.SEES FY 2019 REVENUE $51 MILLION TO $55 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.AVID BIOSERVICES - REVENUE BACKLOG AS OF OCT. 31, 2018 WAS $36 MILLION, MAJORITY OF WHICH IS SEEN RECOGNIZING IN FY 2019.Q2 REVENUE CONTRACT MANUFACTURING REVENUE $10.2 MILLION VERSUS $12.8 MILLION.Q2 REVENUE VIEW $10.9 MILLION -- REFINITIV IBES DATA.
Full Article
Sept 10 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR FIRST QUARTER FISCAL 2019 AND RECENT DEVELOPMENTS.SEES FY 2019 REVENUE $51 MILLION TO $55 MILLION.Q1 LOSS PER SHARE $0.06.AVID BIOSERVICES - FISCAL 2019 PROJECTED REVENUE OF $51 MILLION TO $55 MILLION REAFFIRMED.
Full Article
March 1 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES SELECTED BY ACUMEN PHARMACEUTICALS TO LEAD PROCESS DEVELOPMENT AND CLINICAL MANUFACTURE OF NOVEL ALZHEIMER’S DISEASE CANDIDATE.AVID BIOSERVICES - ACUMEN PHARMA SELECTED CO TO PROVIDE PROCESS DEVELOPMENT, CLINICAL MANUFACTURING SERVICES IN SUPPORT OF ACU193.
Full Article
Feb 26 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER.AVID BIOSERVICES - PAUL LYTLE TO RESIGN AS CFO.AVID BIOSERVICES INC - SEARCH FOR LYTLE'S REPLACEMENT HAS BEEN INITIATED.
Full Article
Feb 23 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES INC SAYS PAUL LYTLE GAVE NOTICE OF HIS VOLUNTARY RESIGNATION AS CFO OF CO - SEC FILING.AVID BIOSERVICES INC - COMPANY IS INITIATING A SEARCH FOR ITS NEXT CFO.
Full Article
Feb 15 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.00 MILLION COMMON SHARES PRICED AT $2.25PER SHARE.SAYS PUBLIC OFFERING OF 9.00 MILLION COMMON SHARES PRICED AT $2.25PER SHARE.
Full Article
Feb 14 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.AVID BIOSERVICES INC - INTENDS TO USE NET PROCEEDS FROM OFFERING FOR EXPANSION OF ITS CONTRACT MANUFACTURING BUSINESS AND GENERAL CORPORATE PURPOSES.
Full Article
Feb 12 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES AND ONCOLOGIE ENTER INTO ASSET ASSIGNMENT AND PURCHASE AGREEMENT FOR AVID’S PS-TARGETING PROGRAM INCLUDING BAVITUXIMAB.AVID BIOSERVICES INC - AVID WILL RECEIVE $8 MILLION IN UPFRONT PAYMENTS FROM ONCOLOGIE PAID OVER A PERIOD OF SIX MONTHS FROM EXECUTION DATE OF AGREEMENT.AVID BIOSERVICES INC - AVID WILL BE ELIGIBLE TO RECEIVE UP TO $95 MILLION IN DEVELOPMENT, REGULATORY AND COMMERCIALIZATION MILESTONES.AVID BIOSERVICES - ONCOLOGIE TO BE RESPONSIBLE FOR FUTURE RESEARCH, DEVELOPMENT & COMMERCIALIZATION OF BAVITUXIMAB, RELATED INTELLECTUAL PROPERTY COSTS.AVID BIOSERVICES INC - ONCOLOGIE WILL ENTER INTO DEAL WITH AVID FOR FUTURE CONTRACT DEVELOPMENT AND MANUFACTURING ACTIVITIES IN SUPPORT OF BAVITUXIMAB.
Full Article
Earnings vs. 
Estimates